'A Real Regulatory Dilemma Here': What We Heard This Week

(MedPage Today) -- "It's a real regulatory dilemma here." -- Donald Kohn, MD, of the University of California Los Angeles, at an FDA advisory committee meeting to discuss whether the bleeding reversal agent andexanet alfa (Andexxa) should get...